Rapid, High Sensitivity Quantification of a Proteolysis Targeting Chimera, PROTAC, in Rat Plasma From a Microsampling DMPK Study Using UPLC-MS/MS

Importance of the Topic

Proteolysis Targeting Chimeras (PROTACs) offer a novel approach to drug development by harnessing the proteasome to degrade disease-related proteins. Accurate pharmacokinetic profiling of PROTAC candidates is essential to guide early stage development and clinical translation. Microsampling techniques enable reduced animal use and improved data quality in DMPK studies.

Study Objectives and Overview

This study aimed to establish a rapid, high-sensitivity reversed-phase UPLC-MS/MS assay for quantifying a PROTAC derivative of gefitinib in rat plasma collected via microsampling. The method covers a dynamic range suitable for pharmacokinetic profiling following subcutaneous dosing.

Methodology

• Animal dosing: Male Wistar rats received 10 mg/kg PROTAC gefitinib subcutaneously. Serial plasma samples were collected at multiple time points over 24 h.
• Sample preparation: 10 µL plasma was acidified, spiked with deuterated internal standard, and processed via Oasis HLB solid phase extraction.
• Calibration and QC: Standards spanned 0.25–500 ng/mL, with QC samples at 0.5, 5 and 250 ng/mL. Linearity assessed with 1/X weighting.

Used Instrumentation

• UPLC system: ACQUITY Premier UPLC with HSS T3 column (2.1 × 100 mm, 1.7 µm) at 60 °C
• Mass spectrometer: Xevo TQ Absolute tandem quadrupole with positive ESI and MRM detection
• Software: MassLynx 4.2 for data acquisition and TargetLynx XS for processing

Main Results and Discussion

• Chromatography: High performance surface technology minimized analyte-metal interactions, yielding sharp symmetrical peaks and improved sensitivity.
• Sensitivity: Lower limit of quantification at 0.25 ng/mL, corresponding to 100 fg on column, with no matrix interference.
• Pharmacokinetics: Peak plasma concentration (Cmax) of 71.8 ng/mL at 6 h post dose, elimination half-life of 7.2 h, and AUC0-t of 898 nM·h. Compound remained detectable at 24 h.

Benefits and Practical Applications

• Method offers rapid throughput and high sensitivity for low volume plasma samples.
• Microsampling aligns with 3Rs principles, reducing animal usage while maintaining data quality.
• Wide dynamic range supports robust quantification across dosing studies and early pharmacokinetic profiling.

Future Trends and Potential Applications

Advances in PROTAC development will drive demand for bioanalytical assays capable of quantifying low-abundance bifunctional molecules. Miniaturized sampling techniques combined with inert UPLC surfaces will support efficient DMPK studies. Integration with high-resolution MS and automated sample handling will further enhance throughput and data reliability.

Conclusion

A sensitive UPLC-MS/MS assay using ACQUITY Premier technology and Xevo TQ Absolute demonstrated reliable quantification of a PROTAC in microsampled rat plasma. The method supports detailed pharmacokinetic analysis with minimal sample volume, facilitating the progression of PROTAC candidates through preclinical development.

Reference

• Bekes M et al Nat Rev Drug Discov 21 181–200 2022
• OBrien Laramy MN et al Nat Rev Drug Discov 22 410–427 2023
• Xiao M et al Biomolecules 12 1257 2022
• Kenten JH et al US Patent US6306663B1
• Mullard A Nat Rev Drug Discov 18 237–239 2019